Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, cold rubs, eye drops, troches, and capsules; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, it offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners; and contract manufacturing services. The company provides its products in gastroenterology, anti-infectives, wound care, neonatology and pediatrics, gynaecology, dental, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-analgesic, dermatology, antivirals, lozenges, and contrast media and radio diagnostic therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for JBCHEPHARM
Revenue projections for JBCHEPHARM

JBCHEPHARM's projected revenue decline from last year is likely to make investors cautious. Lower revenues often hurt a company's bottom line, leading investors to be concerned about the company's ability to maintain profitability and deliver strong financial results in the future.

Financial Ratios:

currentRatio 0.000000
forwardPE 27.398748
debtToEquity 0.812000
earningsGrowth 0.142000
revenueGrowth 0.089000
grossMargins 0.660190
operatingMargins 0.236000
trailingEps 43.200000
forwardEps 0.000000

J. B. Chemicals & Pharmaceuticals Limited's Forward PE ratio suggests the stock price is reasonable in relation to earnings. It's not overpriced, providing room for future growth, making the stock a potentially valuable investment for those seeking long-term gains.
Positive gross and operating margins for JBCHEPHARM highlight the company's profitability. These metrics reflect JBCHEPHARM's efficiency in controlling costs while generating strong revenue from its core operations, signaling robust financial health.

Price projections:

Price projections for JBCHEPHARM
Price projections for JBCHEPHARM

Price projections for J. B. Chemicals & Pharmaceuticals Limited have been revised down over time, reflecting a less optimistic outlook. Analysts appear to be adjusting their expectations, signaling concerns about the company's ability to sustain its previous growth levels.

Insider Transactions:

Insider Transactions for JBCHEPHARM
Insider Transactions for JBCHEPHARM


J. B. Chemicals & Pharmaceuticals Limited experienced 60 selling transactions, with market price of 1766.9875040690104.During the period under consideration, no sell transactions took place.An increase in buying activity relative to selling at J. B. Chemicals & Pharmaceuticals Limited's current price might suggest a favorable sentiment among investors. This trend could be interpreted as a sign that the stock has a positive outlook in the near term.

Recommendation changes over time:

Recommendations trend for JBCHEPHARM
Recommendations trend for JBCHEPHARM


A recent buy bias from analysts toward JBCHEPHARM indicates strong confidence in the stock's future performance. This could encourage investors to park their money in JBCHEPHARM, viewing it as a stable and potentially rewarding investment opportunity with promising long-term growth prospects.